Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive
- Patients treated with povorcitinib experienced improvements in total body and facial repigmentation; investigational therapy was well tolerated
- Results were featured as an oral presentation in a late-breaking abstract session at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Incyte INCY today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation (Session: S042 Late-Breaking Research: Session 2) at the 2023 American Academy of Dermatology (AAD) Annual Meeting, held from March 17-21 in New Orleans.
Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores. Specifically, the study met its primary endpoint and patients receiving povorcitinib experienced statistically superior improvements in T-VASI at Week 24 compared to placebo (povorcitinib 15 mg, 19.1%; 45 mg, 17.8%; 75 mg, 15.7% vs. placebo, +2.3%; least squares mean [LSM] difference, P<0.01). Additionally, more patients who received povorcitinib achieved the key secondary endpoint of T-VASI50 (50% reduction from baseline in the T-VASI) at Week 24 (10.5%, 15 mg arm; 15.2%, 45 mg arm; 5.6%, 75 mg arm vs. 3.0%, placebo arm) and continued to improve during an open-label extension period through Week 36 of treatment (28.6%, povorcitinib 15 75 mg arm; 17.2%, 45 mg arm; 15.2%, 75 mg arm; and 3.0%, placebo 75 mg arm), following dose adjustment.
Continue read on benzinga.com